Preclinical Assets Market Size and Forecast 2024-2033|Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG

The Respiratory Syncytial Virus (RSV) Therapeutics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Respiratory Syncytial Virus (RSV) Therapeutics Market:

https://www.thebusinessresearchcompany.com/report/respiratory-syncytial-virus-rsv-therapeutics-global-market-report

According to The Business Research Company’s Respiratory Syncytial Virus (RSV) Therapeutics Global Market Report 2024, The respiratory syncytial virus (rsv) therapeutics market size has grown exponentially in recent years. It will grow from $1.27 billion in 2023 to $1.59 billion in 2024 at a compound annual growth rate (CAGR) of 25.2%. The growth in the historic period can be attributed to disease awareness, advancements in virology, pediatric vulnerability, epidemic outbreaks, vaccine development.

The respiratory syncytial virus (rsv) therapeutics market size is expected to see exponential growth in the next few years. It will grow to $3.69 billion in 2028 at a compound annual growth rate (CAGR) of 23.4%. The growth in the forecast period can be attributed to biologic therapies innovation, emerging antivirals, focus on elderly population, maternal immunization strategies, global research collaborations. Major trends in the forecast period include monoclonal antibodies advancements, nasal vaccines and delivery systems, combination therapies, novel drug delivery systems, home-based treatment options.

The rise in the prevalence of RSV infection is driving the growth of the respiratory syncytial virus (RSV) therapeutics market going forward. RSV is a prevalent respiratory illness that can result in mild to severe respiratory infections, especially in newborns, young children, elderly adults, and people with compromised immune systems. Increasing RSV infections prompt the development of innovative treatments to address the rising need and mitigate the severity of RSV-related complications. For instance, in September 2022, according to the article published by The Lancet, a UK-based book and periodic data publishing organization, around 11,255 new cases of RSV were recorded in the 2021 summer, which is 9.50% more compared to 10,280 cases in winter 2020–21. Therefore, the rise in the prevalence of RSV infection propels the growth of the respiratory syncytial virus (RSV) therapeutics market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12601&type=smp

The respiratory syncytial virus (rsv) therapeutics market covered in this report is segmented –

1) By Drug: Palivizumab, Ribavirin, Other Drugs

2) By Treatment: Immune Prophylaxis, Supportive Care, Antiviral Medications

3) By Dosage Form: Oral, Injectable, Other Dosage Forms

4) By Patient Type: Pediatrics, Adults

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Developing new drugs and vaccines with better efficacy is a key trend gaining popularity in the respiratory syncytial virus (RSV) therapeutics market. Major companies operating in the respiratory syncytial virus (RSV) therapeutics market are focused on developing new drugs and vaccines to sustain their position in the market. For instance, in May 2023, Pfizer Inc., a US-based pharmaceutical manufacturing company, received approval from the Food and Drug Administration, a US-based federal agency responsible for protecting and promoting public health, for ABRYSVO. The bivalent RSV prefusion F (RSVpreF) vaccine ABRYSVO (Respiratory Syncytial Virus Vaccine) is administered to prevent lower respiratory tract sickness caused by RSV in people 60 and older. ABRYSVO is an unadjuvanted vaccine made up of a pair of preF proteins tailored to maximize immunity to RSV A and B varieties, and it has been clinically proven to be safe and productive.

The respiratory syncytial virus (rsv) therapeutics market report table of contents includes:

1. Executive Summary

2. Respiratory Syncytial Virus (RSV) Therapeutics Market Characteristics

3. Respiratory Syncytial Virus (RSV) Therapeutics Market Trends And Strategies

4. Respiratory Syncytial Virus (RSV) Therapeutics Market – Macro Economic Scenario

5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size and Growth

26. South America Respiratory Syncytial Virus (RSV) Therapeutics Market

27. Brazil Respiratory Syncytial Virus (RSV) Therapeutics Market

28. Middle East Respiratory Syncytial Virus (RSV) Therapeutics Market

29. Africa Respiratory Syncytial Virus (RSV) Therapeutics Market

30. Respiratory Syncytial Virus (RSV) Therapeutics Market Competitive Landscape And Company Profiles

Top Major Players: